Trial Profile
iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 04 Apr 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2023.
- 04 Apr 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2023.
- 25 Mar 2022 Planned number of patients changed from 22 to 42.